40:I[185,["/_next/static/chunks/0sxns9k8ywops.js","/_next/static/chunks/11fk-1ie3w6mp.js","/_next/static/chunks/1uc4qdk4uj22c.js","/_next/static/chunks/0jvahffpql9nd.js","/_next/static/chunks/0agcep-t686m_.js","/_next/static/chunks/2_mrasy1s2owt.js","/_next/static/chunks/1nsk8jrr9fqe6.js"],"SendEmailButton"] 42:I[63625,["/_next/static/chunks/0sxns9k8ywops.js","/_next/static/chunks/11fk-1ie3w6mp.js","/_next/static/chunks/1uc4qdk4uj22c.js","/_next/static/chunks/0jvahffpql9nd.js","/_next/static/chunks/0agcep-t686m_.js","/_next/static/chunks/2_mrasy1s2owt.js","/_next/static/chunks/1nsk8jrr9fqe6.js"],"AddToLibraryButton"] 43:I[29721,["/_next/static/chunks/0sxns9k8ywops.js","/_next/static/chunks/11fk-1ie3w6mp.js","/_next/static/chunks/1uc4qdk4uj22c.js","/_next/static/chunks/0jvahffpql9nd.js","/_next/static/chunks/0agcep-t686m_.js","/_next/static/chunks/2_mrasy1s2owt.js","/_next/static/chunks/1nsk8jrr9fqe6.js"],"ShareButton"] 44:I[58016,["/_next/static/chunks/0sxns9k8ywops.js","/_next/static/chunks/11fk-1ie3w6mp.js","/_next/static/chunks/1uc4qdk4uj22c.js","/_next/static/chunks/0jvahffpql9nd.js","/_next/static/chunks/0agcep-t686m_.js","/_next/static/chunks/2_mrasy1s2owt.js","/_next/static/chunks/1nsk8jrr9fqe6.js"],"ProcessEpisodeButton"] 45:I[45269,["/_next/static/chunks/0sxns9k8ywops.js","/_next/static/chunks/11fk-1ie3w6mp.js","/_next/static/chunks/1uc4qdk4uj22c.js","/_next/static/chunks/0jvahffpql9nd.js","/_next/static/chunks/0agcep-t686m_.js","/_next/static/chunks/2_mrasy1s2owt.js","/_next/static/chunks/1nsk8jrr9fqe6.js"],"SignupCTA"] 41:T47f,

The JournalFeed podcast for the week of August 5-9, 2024.

For acute ischemic stroke patients with recent DOAC ingestion who (1) had their DOAC level measured, (2) had DOAC reversal with idarucizumab, or (3) inadvertently received thrombolytics with DOAC subsequently discovered, there was not evidence of increased significant intracranial hemorrhage associated with off-label thrombolytic therapy.

Friday Spoon Feed:

In patients with large vessel occlusions(LVO) presenting 4.5-24 hours after onset, without access to endovascular thrombectomy (ET), tenecteplase(TNK) administration bested standard medical treatment(SMT) in 90-day disability-free recovery.